Fibroblast growth factor receptor 3 gene (FGFR3) mutations in high-grade muscle-invasive urothelial bladder cancer in a Brazilian population: evaluation and prevalence

ABSTRACT

Objective

To understand the feasibility of FGFR3 tests in the Brazilian public health context, and to sample the mutational burden of this receptor in high-grade muscle invasive bladder cancer.

Methods

A total of 31 patients with high-grade muscle-invasive bladder cancer were included in the present study. Either transurethral resection of bladder tumor or radical cystectomy specimens were analyzed. Formalin-fixed paraffin-embedded tissue blocks were sectioned, hematoxylin and eosin stained, and histologic sections were reviewed. Total RNA was extracted using the RNeasy DSP formalin-fixed paraffin-embedded kit. Qualitative results were displayed in Rotor-Gene AssayManager software.

Results

Six patients were excluded. From the samples analyzed, four (16.7%) were considered inadequate and could not have their RNA extracted. Two patients presented FGFR3 mutations, accounting for 9.5% of material available for adequate analysis. The two mutations detected included a Y373C mutation in a male patient and a S249C mutation in a female patient.

Conclusion

FGFR3 mutations could be analyzed in 84% of our cohort and occurred in 9.5% of patients with high-grade muscle invasive bladder cancer in this Brazilian population. FGFR3 gene mutations are targets for therapeutic drugs in muscle-invasive bladder cancer. For this reason, know the frequency of these mutations can have a significant impact on public health policies and costs provisioning.

Urinary bladder neoplasms; Receptor, fibroblast growth factor, type 3; Mutation; Polymerase chain reaction; DNA; Sequence analysis, DNA; Carcinoma, transitional cell

INTRODUCTION

Bladder cancer has a high mutational burden, and fibroblast growth factor receptor 3 gene (FGFR3) is one of the most frequently mutated genes in bladder cancer. It is reported that more than 65% of non-muscle invasive bladder cancer (NMIBC) carry FGFR3 mutations.(¹) A large study evaluated 10,032 bladder cancer and identified 56 different FGFR3 mutations.(²)

The fibroblast growth factor (FGF) family of transmembrane tyrosine kinase receptors mediates proliferation in response to FGF stimulation and has been implicated in the pathogenesis of urothelial cancer. Fibroblast growth factor receptor 1 gene (FGFR1) and FGFR3 are either mutated or overexpressed in the majority of NMIBC.(³) These mutations are less frequently observed in muscle-invasive bladder cancer (MIBC) and less common in high-grade tumors than in low-grade tumors.(⁴)

It can be vital to understand the FGFR3 mutational burden of MIBC, since there are therapeutic agents with clinical benefits for this specific situation.(⁵) Additionally, patients with FGFR3 alterations tend to have a low likelihood of response to chemotherapy and PD-1 and PD-L1 inhibitors.(⁵-⁷) FGFR3 mutations are currently targets for therapeutic agents in bladder cancer. Erdafinib has already been approved by the Food and Drug Administration (FDA) for metastatic bladder cancer after first-line therapy. However, this agent is only approved if an FGFR3 mutation is detected.(⁵)

The access to comprehensive genomic tests in Brazil is still limited, and the prevalence of FGFR3 mutations among Brazilian MIBC patients is not well known. Brazil is a country with a sizeable territorial extension, and some degree of genetic background heterogeneity may exist in the population.(⁸)Precision medicine and targeted therapies are already a reality in the pipeline of bladder cancer treatment.(⁹) In such a context, knowledge of the molecular profile of MIBC in Brazil is fundamental to define better public health strategies, for it can have major impacts.(¹⁰)

OBJECTIVE

To understand the feasibility of FGFR3 tests in the Brazilian public health context, and to sample the mutational burden of this receptor in high-grade muscle invasive bladder cancer.

METHODS

From May 2020 to November 2020 a total of 31 patients with high-grade MIBC were included in the present study. Either transurethral resection of bladder tumor (TURBT) or radical cystectomy specimens were available for analysis.

Formalin-fixed paraffin-embedded (FFPE) tissue blocks with tumor samples were previously identified. All hematoxylin and eosin stained histologic sections from specimens were reviewed. Index tumor (highlighted on slides) was defined as focusing on the worst pattern and area with muscle-invasion. Urothelial carcinomas were staged according to the Union for International Cancer Control (UICC) criteria, and graded according to World Health Organization (WHO) criteria.

The Institutional Medical Ethics Committee of the Faculdade de Medicina do ABC (FMABC) approved the present study, CAAE: 31079120.6.0000.0082, protocol # 4.039.916, and all patients signed the Informed Consent Form.

Genomic RNA

As per the manufacturer protocols (Qiagen, Hilden, Germany), total RNA was extracted from FFPE urothelial tumor samples using the RNeasy DSP FFPE kit. Purified RNA was then reversely transcribed using reverse transcriptase to generate cDNA for real-time PCR analysis. Qualitative results were displayed in Rotor-Gene AssayManager software, informing the system operator if one or more of the four-point mutations and two fusions in the FGFR3 gene detected by the kit were present in each sample. The therascreen FGFR RGQ RT-PCR kit is a qualitative in vitro diagnostic test for the detection of two point mutations in exon 7 – p.R248C (c.742C>T) and p.S249C (c.746C>G) –, two-point mutations in exon 10 – p.G370C (c.1108G>T) and p.Y373C (c.1118A>G) –, and two fusions – FGFR3-TACC3v1 and FGFR3-TACC3v3 – in the FGFR3 gene.(¹¹) Fibroblast growth factor receptor mutations tested included R248C, G370C, S249C, Y373C, TAC3V3, BAIAP2L1, CASP7, TACC3V1, and BICC1.

Statistical analysis

Data were analyzed using STATA 14.0 (StataCorp LP, College Station, Texas, United States). Frequency tables were chosen for descriptive analyses. Chi-squared and Fisher’s exact test were chosen to assess the frequency of responses among groups. For continuous variables, we used the Mann-Whitney test, and p<0.05 was considered significant.

RESULTS

Patients and tumors

A total of 31 patients were included in the present study. All patients had a histologic diagnosis of high-grade muscle-invasive urothelial carcinoma of the urinary bladder. Patients’ demographics are presented in table 1. Of the total, two patients refused to continue on the study, and four could not be contacted to give consent.

Table 1
Patients’ demographics

Demographics
Age, years	65.0±8.2
BMI, kg/m2	27.0±4.4
Ethnicity
White	17 (68)
Black	1 (4)
Others	7 (28)
Sex
Male	14 (56)
Female	11 (44)
Smoking status
Smoker	9 (36)
Former smoker	8 (32)
2Never smoked	6 (24)
Unknown	2 (8)
T staging
2	18 (72)
3	4 (16)
4	3 (12)
N staging
Negative	19 (76)
Positive	6 (24)
M staging
Negative	21 (84)
Positive	4 (16)
Serum hemoglobin, g/dL	13.1±2.2
Creatinine, mg/dL	1.1±0.7
Creatinine clearence, mL/min/1.73m2	56.0±30.2

• Results expressed as media ± standard deviation or n (%).
• BMI: body mass index.

FGFR3 mRNA analysis and mutations

From the samples analyzed, four (16.7%) were considered inadequate samples and could not have their RNA extracted, remaining 21 patients for further analysis. Two of the patients presents FGFR3 mutations, representing 9.5% of material available for adequate analysis. The two mutations detected included a Y373C mutation in a male patient, and a S249C mutation in a female patient. These results are represented in figure 1.

Figure 1
Tests results and FGFR3 mutations

DISCUSSION

It is known that FGFR3 mutations are common in bladder cancer. However, they tend to occur more frequently in non-muscle invasive and low-grade tumors. It is less common in muscle-invasive and high-grade tumors. FGFR3 mutations are less common in these patients, but this population arouses great interest. They have a higher risk of developing metastatic disease. In recent years, FGFR3 inhibitors, such as erdafitinib, have been approved by the FDA for patients with metastatic urothelial carcinoma after first-line treatment. Therefore, our study evaluated the expression of FGFR3 mutations in patients with high-grade MIBC, in a Brazilian sample.

We had some interesting findings. First, the frequency of FGFR3 mutation in our cohort was relatively low, with 9.5% in the tumors analyzed. Although our sample size was small, we found results very similar to those from other studies.(¹²) Gust et al., also reported FGFR3 mutations in 11% of patients, in a similar cohort from Europe, with Greek and Spanish patients.(¹³) Another study found 6% of mutations.(¹⁴)These numbers are much fewer than those found in non-invasive and low-grade bladder cancer.(⁴)

Previous studies identified the S249C mutation (TCC→TGC), which accounts for 62% of all recurrent FGFR3 mutations, and Y373C as the second most frequent, accounting for approximately 29% of all mutations.(¹⁵-¹⁸) The Y373C and the S249C mutations were found in the present study. They are Apolipoprotein B mRNA Editing Catalytic Polypeptide-like (APOBEC)-mediated mutations, what might explain their overrepresentation in bladder cancer as compared to other FGFR3 alterations.(²) Our sample size was small and we could identify only these two cases; however, this finding is in accordance with those of larger cohorts. Genetic mutations can vary among different populations.(⁸) For this reason, it is crucial to analyze a Brazilian sample.

Our study has several limitations. First, our cohort of patients is small. Additionally, mutation analysis of FGFR3 was not performed in FFPE tissue. Tumor heterogeneity and processing limitations were responsible for some limitations of this method. Nonetheless, it was possible to validate externally with other cohorts of patients, demonstrating similar results. Thus, our observation that 9.5% of high-grade MIBC sampled from the primary tumor had FGFR3 mutations is reasonable based on the published literature.

Additionally, four of our cases could not be examined due to technical limitations. In 16.7% of cases, the sample was inadequate for RNA extraction. Our study was performed in FFPE tissue. It is known that this material might have some limitations.(¹⁹) Some variables, such as cold ischemia time, quality of formalin (10%, buffered), paraffin quality, and storage conditions are critical.(²⁰) These aspects of the analysis are cornerstones for precision medicine. Biomolecular markers rely on good-quality material. Our study demonstrates that we have much to improve in this field. A third of our samples were rendered improper for further RNA extraction and could not be analyzed. When a TURBT is performed, details such as the cautery configuration or the amount of time to store the tissue in the formalin, can significantly impact this specific outcome.

CONCLUSION

FGFR3 gene mutations could be analyzed in 84% of our cohort, and they occurred in 9.5% of patients with high-grade muscle invasive bladder cancer in this Brazilian population. FGFR3 gene mutations are targets for therapeutic drugs in muscle invasive bladder cancer. For this reason, know the frequency of these mutations can have a significant impact on public health policies and costs provisioning.

REFERENCES

• ¹
  Hedegaard J, Lamy P, Nordentoft I, Algaba F, Høyer S, Ulhøi BP, et al. Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell. 2016;30(1):27-42.
• ²
  Shi MJ, Meng XY, Lamy P, Banday AR, Yang J, Moreno-Vega A, et al. APOBEC-mediated mutagenesis as a likely cause of fgfr3 s249c mutation over-representation in bladder cancer. Eur Urol. 2019;76(1):9-13.
• ³
  Lindgren D, Liedberg F, Andersson A, Chebil G, Gudjonsson S, Borg A, et al. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene. 2006;25(18):2685-96.
• ⁴
  Billerey C, Chopin D, Aubriot-Lorton MH, Ricol D, Gil Diez de Medina S, Van Rhijn B, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol. 2001;158(6):1955-9.
• ⁵
  Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O’Hagan A, Avadhani A, Siefker-Radtke AO; BLC2001 Study Group. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2019;381(4):338-48.
• ⁶
  Karkera JD, Cardona GM, Bell K, Gaffney D, Portale JC, Santiago-Walker A, et al. Oncogenic characterization and pharmacologic sensitivity of activating Fibroblast Growth Factor Receptor (FGFR) genetic alterations to the selective FGFR inhibitor erdafitinib. Mol Cancer Ther. 2017;16(8):1717-26.
• ⁷
  Nogova L, Sequist LV, Perez Garcia JM, Andre F, Delord JP, Hidalgo M, et al. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. J Clin Oncol. 2017;35(2):157-165. Erratum in: J Clin Oncol. 2017;35(8):926. Erratum in: J Clin Oncol. 2019;37(4):358.
• ⁸
  Mascarenhas E, Gelatti AC, Araújo LH, Baldotto C, Mathias C, Zukin M, et al. Comprehensive genomic profiling of Brazilian non-small cell lung cancer patients (GBOT 0118/LACOG0418). Thorac Cancer. 2021;12(5):580-7.
• ⁹
  Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, et al. Bladder cancer, version 3.2020, nccn clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(3):329-54.
• ¹⁰
  Korkes F, Maluf F. Increasing costs from bladder cancer in the Brazilian Health System: the role of establishing public health policies. Int Braz J Urol. 2021;47(2)443-7.
• ¹¹
  QIAGEN©. therascreen FGFR RGQ RT-PCR Kit (CE-IVD). Germany: QIAGEN; 2021 [cited 2021 Feb 28]. Available from: https://www.qiagen.com/br/products/diagnostics-and-clinical-research/oncology/therascreen-solid-tumor/therascreen-fgfr-rgq-rt-pcr-kit-ce-ivd/#orderinginformation
  » https://www.qiagen.com/br/products/diagnostics-and-clinical-research/oncology/therascreen-solid-tumor/therascreen-fgfr-rgq-rt-pcr-kit-ce-ivd/#orderinginformation
• ¹²
  van Rhijn BW, Mertens LS, Mayr R, Bostrom PJ, Real FX, Zwarthoff EC, et al. FGFR3 mutation status and fgfr3 expression in a large bladder cancer cohort treated by radical cystectomy: implications for anti-fgfr3 treatment? Eur Urol. 2020;78(5):682-7.
• ¹³
  Gust KM, McConkey DJ, Awrey S, Hegarty PK, Qing J, Bondaruk J, et al. Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer. Mol Cancer Ther. 2013;12(7):1245-54.
• ¹⁴
  Ross JS, Wang K, Al-Rohil RN, Nazeer T, Sheehan CE, Otto GA, et al. Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy. Mod Pathol. 2014;27(2):271-80.
• ¹⁵
  Bodoor K, Ghabkari A, Jaradat Z, Alkhateeb A, Jaradat S, Al-Ghazo MA, et al. FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population. Cancer Epidemiol. 2010;34(6):724-32.
• ¹⁶
  Hernández S, López-Knowles E, Lloreta J, Kogevinas M, Amorós A, Tardón A, et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol. 2006;24(22):3664-71.
• ¹⁷
  van Oers JM, Zwarthoff EC, Rehman I, Azzouzi AR, Cussenot O, Meuth M, et al. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur Urol. 2009;55(3):650-7.
• ¹⁸
  Shi MJ, Meng XY, Lamy P, Banday AR, Yang J, Moreno-Vega A, et al. APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer. Eur Urol. 2019;76(1):9-13.
• ¹⁹
  Compton CC, Robb JA, Anderson MW, Berry AB, Birdsong GG, Bloom KJ, et al. Preanalytics and precision pathology: pathology practices to ensure molecular integrity of cancer patient biospecimens for precision medicine. Arch Pathol Lab Med. 2019;143(11):1346-63. Review.
• ²⁰
  Amemiya K, Hirotsu Y, Oyama T, Omata M. Relationship between formalin reagent and success rate of targeted sequencing analysis using formalin fixed paraffin embedded tissues. Clin Chim Acta. 2019;488:129-34.

Publication Dates

• Publication in this collection
  01 Apr 2022
• Date of issue
  2022

History

• Received
  16 Jan 2021
• Accepted
  10 June 2021